Products - Ear, nose and throat conditions | Topic

Showing 11 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen (TA1087)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 August 2025
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 August 2026
Botulinum toxin injection to cricopharyngeal muscle for retrograde cricopharyngeal dysfunction (RCPD)
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Digital hearing aids (Provisional title)
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
TBC
Digital tools and platforms to support the early detection and initial diagnosis of hearing loss
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mercaptamine hydrochloride for treating corneal cystine crystal deposits in people 6 months to under 2 years with cystinosis [TSID12261]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Technologies to support self-monitoring of vision change for people with macular disease (provisional title)
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 September 2026

Ear, nose and throat conditions Products

Filter

Product type

Guidance programme

Status

New and updated
1 selected

Showing 11 products

Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen (TA1087)

Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537

Botulinum toxin injection to cricopharyngeal muscle for retrograde cricopharyngeal dysfunction (RCPD)

Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]

Digital hearing aids (Provisional title)

Digital tools and platforms to support the early detection and initial diagnosis of hearing loss

Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]

Mercaptamine hydrochloride for treating corneal cystine crystal deposits in people 6 months to under 2 years with cystinosis [TSID12261]

Technologies to support self-monitoring of vision change for people with macular disease (provisional title)

Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

Ear, nose and throat conditions Products

Filter

Product type

Guidance programme

Status

New and updated1 selected

Showing 11 products

New and updated
1 selected